AstraZeneca sets ambition to deliver $80 billion Total Revenue by 2030
- Details
- Category: AstraZeneca

Novartis enters agreement to acquire Mariana Oncology, strengthening radioligand therapy pipeline
- Details
- Category: Novartis

The transaction bolsters the Novartis RLT pipeline and expands the company's research infrastructure and clinical supply capabilities, supporting Novartis strategic priorities in oncology and RLT platform innovation.
U.S. FDA approves Pfizer's BEQVEZ™ (fidanacogene elaparvovec-dzkt), a one-time gene therapy for adults with Hemophilia B
- Details
- Category: Pfizer

AskBio receives FDA Fast Track Designation for AB-1002 investigational gene therapy program in congestive heart failure
- Details
- Category: Bayer

European Commission approves Pfizer's EMBLAVEO® for patients with multidrug-resistant infections and limited treatment options
- Details
- Category: Pfizer

AskBio presents 18-month Phase Ib trial results of AB-1005 gene therapy for patients with Parkinson's disease
- Details
- Category: Bayer

The study met its primary objective, which was to evaluate the safety of a one-time bilateral delivery of AB-1005 directly to the putamen.
Bayer and Thermo Fisher Scientific collaborate to increase patient access to precision cancer medicines
- Details
- Category: Bayer

More Pharma News ...
- Bayer and Aignostics to collaborate on next generation precision oncology
- AstraZeneca to acquire Amolyt Pharma, expanding late-stage rare disease pipeline
- European Commission approves Pfizer's PREVENAR 20® to help protect infants and children against pneumococcal disease
- Novartis presents new data on safety and efficacy of Zolgensma
- Pfizer announces positive top-line data for full season two efficacy of ABRYSVO® for RSV in older adults
- Bayer receives U.S. FDA Breakthrough Therapy designation for BAY 2927088 for non-small cell lung cancer harboring HER2 activating mutations
- European Commission approves Pfizer's VELSIPITY® for patients with moderately to severely Active ulcerative colitis